The Oncology Brothers Discuss ADAURA Trial Findings of Osimertinib for EGFR-Mutated NSCLC

The Oncology Brothers—Rahul Gosain, MD, of the University of Rochester, and Rohit Gosain, MD, of the UPMC Hillman Cancer Center—were live at the 2023 ASCO^® Annual Meeting in Chicago, Illinois, to discuss findings from the phase 3 ADAURA trial. The updated data showed an overall survival benefit with osimertinib for treating EGFR-mutated non-small cell lung cancer (NSCLC).

The Oncology Brothers were joined by Balazs Halmos, MD, of the Montefiore Einstein Cancer Center, who gave his perspective on the findings, calling the results “transformational.” He also stressed the importance of biomarker testing to guide treatment decisions.

Trial Findings

The phase 3 ADAURA trial results presented at ASCO showed that adjuvant osimertinib induced “an unprecedented, highly statistically significant and clinically meaningful OS benefit in patients with EGFR-mutated stage IB-IIIA NSCLC.”

The study randomized 682 patients to receive osimertinib 80 mg once daily (n=339) or placebo (n=343). In the overall patient population (stage IB-IIIA), the 5-year OS rate was 88% in the osimertinib group and 78% in the placebo cohort (hazard ratio [HR], 0.49; P<.0001). In patients with stage II-IIIA disease, the 5-year OS rate was 85% with osimertinib versus 73% with placebo (HR, 0.49; P=.0004). The 36-, 48-, and 60-month OS rates were 94%, 91%, and 85%, respectively, in the osimertinib arm and 86%, 80%, and 73%, respectively, in the placebo cohort.

“ADAURA is the first global phase 3 study to demonstrate a statistically significant disease-free survival and OS benefit with targeted treatment for patients with EGFR-mutated stage IB to IIIA NSCLC,” the study authors concluded.